S'abonner

Respiratory rate‑oxygenation (ROX) index for predicting high-flow nasal cannula failure in patients with and without COVID-19 - 28/11/23

Doi : 10.1016/j.ajem.2023.09.036 
Hyojeong Kwon a, Seung Won Ha a, Boram Kim b, Bora Chae a, Sang-Min Kim a, Seok-In Hong a, June-Sung Kim a, Youn-Jung Kim a, Seung Mok Ryoo a, Won Young Kim a,
a Department of Emergency Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea 
b Department of Emergency Medicine, Korea University Ansan Hospital, Ansan, Republic of Korea 

Corresponding author: Department of Emergency Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-Gil, Songpa-gu, Seoul 05505, Republic of Korea.Department of Emergency Medicine, Asan Medical CenterUniversity of Ulsan College of Medicine88 Olympic-ro 43-Gil, Songpa-guSeoul05505Republic of Korea

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Background

The predictive value of the respiratory rate‑oxygenation (ROX) index for a high-flow nasal cannula (HFNC) in patients with COVID-19 with acute hypoxemic respiratory failure (AHRF) may differ from patients without COVID-19 with AHRF, but these patients have not yet been compared. We compared the diagnostic accuracy of the ROX index for HFNC failure in patients with AHRF with and without COVID-19 during acute emergency department (ED) visits.

Methods

We performed a retrospective analysis of patients with AHRF treated with an HFNC in an ED between October 2020 and April 2022. The ROX index was calculated at 1, 2, 4, 6, 12, and 24 h after HFNC placement. The primary outcome was the failure of the HFNC, which was defined as the need for subsequent intubation or death within 72 h. A receiver operating characteristic (ROC) curve was used to evaluate discriminative power of the ROX index for HFNC failure.

Results

Among 448 patients with AHRF treated with an HFNC in an ED, 78 (17.4%) patients were confirmed to have COVID-19. There was no significant difference in the HFNC failure rates between the non-COVID-19 and COVID-19 groups (29.5% vs. 33.3%, p = 0.498). The median ROX index was higher in the non-COVID-19 group than in the COVID-19 group at all time points. The prognostic power of the ROX index for HFNC failure as evaluated by the area under the ROC curve was generally higher in the COVID-19 group (0.73–0.83) than the non-COVID-19 group (0.62–0.75). The timing of the highest prognostic value of the ROX index for HFNC failure was at 4 h for the non-COVID-19 group, whereas in the COVID-19 group, its performance remained consistent from 1 h to 6 h. The optimal cutoff values were 6.48 and 5.79 for the non-COVID-19 and COVID-19 groups, respectively.

Conclusions

The ROX index had an acceptable discriminative power for predicting HFNC failure in patients with AHRF with and without COVID-19 in the ED. However, the higher ROX index thresholds than those in previous publications involving intensive care unit (ICU) patients suggest the need for careful monitoring and establishment of a new threshold for patients admitted outside the ICU.

Le texte complet de cet article est disponible en PDF.

Keywords : COVID-19, High-flow nasal cannula, Acute hypoxemic respiratory failure, ROX index, Endotracheal intubation, Discriminative power


Plan


© 2023  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 75

P. 53-58 - janvier 2024 Retour au numéro
Article précédent Article précédent
  • Prediction of the neurological outcomes post-cardiac arrest: A prospective validation of the CAST and rCAST
  • Kazuya Kikutani, Mitsuaki Nishikimi, Kota Matsui, Atsushi Sakurai, Kei Hayashida, Nobuya Kitamura, Takashi Tagami, Taka-aki Nakada, Shigeyuki Matsui, Shinichiro Ohshimo, Nobuaki Shime, on behalf of the SOS-KANTO 2017 Study Group
| Article suivant Article suivant
  • Is the shock index correlated with blood loss? An experimental study on a controlled hemorrhagic shock model in piglets
  • Thomas Sanchez, Fabien Coisy, Laura Grau-Mercier, Céline Occelli, Florian Ajavon, Pierre-Géraud Claret, Thibaut Markarian, Xavier Bobbia

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.